Just to remind ourselves that Opthea is a anti VEGF drug and Fovista is a "platelet derived growth factor (PDGF)" drug so as not to confuse the Opthotech result and implications for OPT. More signs of efficacy from the phase 2A trial to be reported late 1st qtr 2017 for OPT302 will definitely put OPT centre stage.
http://www.ophthotech.com/product-candidates/fovista/
really really good, page-6
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |